Trial Profile

A Phase Ib Study of AZD6738 for Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Progressing on Front-Line Therapy

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 19 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ceralasertib (Primary)
Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
Focus Adverse reactions

Most Recent Events

12 Mar 2024 Planned primary completion date changed from 31 May 2022 to 31 May 2024.
17 Jun 2022 Results assessing inhibition of ATR in patients with MDS or CMML, particularly those who harbor SF gene mutations, presented at the 27th Congress of the European Haematology Association.
14 Dec 2021 Results of Safety and Preliminary Activity from a Phase Ib/II Study presented at the 63rd American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com